-
AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans
12 Nov 2025 12:00 GMT
… PhD focused on mesothelioma; principal investigator on multiple mesothelioma studies and … to peer-reviewed mesothelioma publications. Mesothelioma at a glance Mesothelioma is an aggressive … "Item 3 – Key Information-Risk Factors" in the Company…
-
AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026
27 Oct 2025 12:00 GMT
… epithelial and non-epithelioid mesothelioma models, reduces tumor … epithelial and non-epithelioid mesothelioma models
Quantified anti-tumor … an initial focus on mesothelioma, advancing toward first- … Item 3 – Key Information-Risk Factors" in the Company…
-
AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4’s Path to First- Patient Dosing
25 Oct 2025 16:30 GMT
… -in-human evaluation. In human mesothelioma spheroid systems, hypoxia-linked adenosine … monotherapy activity in an immunocompetent mesothelioma model, and combination treatment with … "Item 3 – Key Information-Risk Factors" in the Company…
-
AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth
22 Oct 2025 16:00 GMT
… in a human epithelioid mesothelioma cell line, associated with … an immunocompetent in vivo mesothelioma model, TT-4 monotherapy … an initial focus on mesothelioma, advancing toward first-patient … ;Item 3 – Key Information-Risk Factors" in the Company…
-
AlphaTON Capital and Subsidiary Cyncado Therapeutics Pioneer Convergence of Digital Assets and Oncology Innovation: Exploring Tokenization Framework for Mesothelioma Program as it Advances Toward Q1 2026 First Patient Dosing
08 Oct 2025 11:16 GMT
… and patient outcomes." The mesothelioma tokenization initiative represents the first … -601) protocol, with a larger mesothelioma-focused study planned immediately thereafter … "Item 3 – Key Information-Risk Factors" in the Company…
-
Asbestos Exposure: A Major Risk Factor for Mesothelioma
01 Jul 2025 01:38 GMT
Asbestos Publicity: A Main Danger Issue for Mesothelioma
Asbestos publicity is a serious threat issue for mesothelioma, a uncommon sort of most cancers that impacts the skinny lining of the physique’s inside organs, mostly the lungs. Mesothelioma has been …
-
The Role of Asbestos in Peritoneal Mesothelioma: Causes and Risk Factors
12 Jun 2025 23:34 GMT
The Position of Asbestos in Peritoneal Mesothelioma: Causes and Threat Elements
Mesothelioma is a uncommon and aggressive type of most cancers that impacts the mesothelial cells, that are the cells that line the pleural, peritoneal, and pericardial …
-
Breakthrough discovery reveals treatable form of familial mesothelioma
02 Sep 2025 18:54 GMT
… . Asbestos exposure is the primary risk factor. Median survival time after diagnosis … features and clinical characteristics. Furthermore, mesothelioma risk in subjects with BAP1 … Dr. Carbone proposed that familial mesothelioma was caused by genetics (Roushdy …
-
Sound Off: Mesothelioma registry will improve veteran life expectancy
13 Aug 2025 08:30 GMT
… including surveys on asbestos exposure risk factors and protocols to protect patient … continues to see disproportionately high mesothelioma rates, particularly among veterans. … plan of establishing a national mesothelioma registry already represents a …
-
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
01 Dec 2025 15:01 GMT
… stroke. Patients with known risk factors for thromboembolism (splenectomy or … patients with unresectable malignant pleural mesothelioma (MPM). OPDIVO® (nivolumab), … previously untreated unresectable malignant pleural mesothelioma, in combination with YERVOY …